News
04-06-2011, 05:11 AM
Circadian Technologies announced today that its licensee ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, has advised that it has commenced the first Phase 1 clinical trial of its fully-human monoclonal antibody IMC-3C5.
More... (http://www.news-medical.net/news/20110406/ImClone-Systems-initiates-IMC-3C5-Phase-1-trial-in-patients-with-advanced-solid-tumours.aspx)
More... (http://www.news-medical.net/news/20110406/ImClone-Systems-initiates-IMC-3C5-Phase-1-trial-in-patients-with-advanced-solid-tumours.aspx)